|
| |
Talecris BiotherapeuticsTalecris Biotherapeutics is a new company proud to inherit a legacy of more than 60 years of providing lifesaving and life-enhancing plasma-derived therapeutic proteins. Through the assets of Bayer Biological Products’ plasma business, Talecris’ heritage of patient care innovations in therapeutic proteins dates back to the blood-derived products Cutter Laboratories began to produce in the early 1940s. Cutter and its successor companies, including Miles Laboratories and Bayer, were recognized in the industry as producers of innovative products, starting with the development of albumin and continuing with other products for immune deficiencies, genetic lung disease, hemophilia, and passive immunity. Talecris, having inherited this solid foundation of unparalleled expertise and experience, is now uniquely positioned to create a new standard of excellence in the field of biotherapeutics.
| Contact Details: |
| PO Box 1105264101 Research Commons
79 T.W. Alexander Drive |
| Research Triangle Park |
| North Carolina |
| 27709 |
| United States of America |
| Tel: | (919) 316-6300 |
| Fax: | |
| Email: | HR@talecris.com |
| WWW: | www.talecris.com/
|
|
Loading...
|
Recent Publications by Talecris Biotherapeutics: |  |
Discovery and analysis of a novel parvovirus B19 Genotype 3 isolate in the United States.
BACKGROUND: Parvovirus B19 (B19V) is a pathogen frequently identified in... | 1st August, 2009
| Department of Pathogen Safety, Talecris Biotherapeutics, Raleigh Test
| Transfusion. 2009 Jul;49(7):1488-92. Epub 2009 Mar 31.
DOI Direct Link |
Structure and activity of plasmin and other direct thrombolytic agents.
The physiological or pharmacological dissolution of thrombi is ultimately... | 14th January, 2009
| Talecris Biotherapeutics,
| Thromb Res. 2008;122 Suppl 3:S3-8. Epub 2008 Aug 21.
DOI Direct Link |
Simplified recombinant plasmin: production and functional comparison of a novel thrombolytic molecule with plasma-derived plasmin.
A simplified and fully functional deletion mutant of plasminogen was... | 18th October, 2008
| Talecris Biotherapeutics, 85 TW Alexander Dr., Research Triangle Park, NC
| Thromb Haemost. 2008 Sep;100(3):413-9.
|
Blood inhibitory capacity toward exogenous plasmin.
Stabilized, active plasmin is a novel thrombolytic for direct delivery to... | 15th June, 2007
| Talecris Biotherapeutics, Research Triangle Park, North Carolina 27709,
| Blood Coagul Fibrinolysis. 2007 Apr;18(3):241-6.
DOI Direct Link |
Yield improvement for manufacture of alpha-proteinase inhibitor.
BACKGROUND AND OBJECTIVES: The aim of this study was to increase the yield... | 1st March, 2007
| Talecris Biotherapeutics, Inc., Clayton, NC, USA.
| Vox Sang. 2006 Nov;91(4):309-15.
DOI Direct Link |
→View more Talecris Biotherapeutics research publications. |
Press Releases on Talecris Biotherapeutics:
|
 |
| Reportlinker Adds Blood Banking and Blood Products - Global Market Perspective |
25th November, 2009 |
Reportlinker |
NEW YORK, Nov. 25 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Blood Banking and Blood Products - Global Market Perspective
http://www
|
| Reportlinker Adds Immunotherapies and Vaccines for Nontraditional Indications |
26th October, 2009 |
Reportlinker |
NEW YORK, Oct. 26 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue.
Reportlinker Adds Immunotherapies and Vaccines for Nontraditional
|
| Talecris Biotherapeutics Receives FDA Approval for PROLASTIN(R)-C |
19th October, 2009 |
Talecris Biotherapeutics |
RESEARCH TRIANGLE PARK, N.C., Oct. 19 /PRNewswire-FirstCall/ -- Talecris Biotherapeutics (Nasdaq: TLCR) today received approval from the U.S. Food and Drug Administration for PROLASTIN®-C (Alpha1
|
| The Alpha-1 Foundation Awards Two Research Grants with Support from Talecris Biotherapeutics, Inc. |
13th October, 2009 |
Talecris Biotherapeutics, Inc. and The Alpha-1 Foundation |
RESEARCH TRIANGLE PARK, N.C. and MIAMI, Oct. 13 /PRNewswire-FirstCall/ -- The Alpha-1 Foundation announced today that it has awarded two research grants to study how genetic variations in the alpha-1
|
| CSL Limited and Talecris Biotherapeutics Agree to Terminate Merger Agreement |
8th June, 2009 |
CSL Limited |
MELBOURNE, Australia and RESEARCH TRIANGLE PARK, N.C., June 8 /PRNewswire/ -- CSL Limited (ASX: CSL) and Talecris Biotherapeutics, Inc. announced today that they have mutually agreed to terminate
|
 Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.
This page has been viewed 699 times since April 2007, the link to the organisation's website has been followed 101 times Recent Search Terms used to find this page: prolastin c yield | Talecris Logo | talecris | talecris diabetes | Talecris Biotherapeutics Logo | talecris bio | talecris bio | talecris | talecris | P.O. Box 1105264101 Research Commons North Carolina 27709 | . Search for more companies in Research Triangle Park Search for more companies in North Carolina This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.BioPortfolio search results for Talecris Biotherapeutics |
